Trius Therapeutics, which focuses on the discovery, development and commercialization of antibiotics for serious infections, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2004 and and has not generated any revenue from product sales to date, plans to list on the NASDAQ under the symbol TSRX. Credit Suisse is the sole bookrunner on the deal, with Piper Jaffray, Canaccord Adams and JMP Securities acting as managers. No pricing terms were disclosed.
